PPIDT00250
Drug Information
| Name | Obinutuzumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB08935 |
| Type | biotech |
| Indication | Obinutuzumab, in combination with [chlorambucil], is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia.[L50617] It is also used to treat follicular lymphoma, in combination with [bendamustine] followed by monotherapy, in patients who relapsed after or are refractory to, a [rituximab]-containing regimen.[L50617] Obinutuzumab is also used in combination with chemotherapy followed by monotherapy to treat previously untreated stage II bulky, III or IV follicular lymphoma in adult patients achieving at least a partial remission.[L50617] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | — |
25 MG/ML
|
| Injection, solution | Intravenous |
1000 mg/40ml
|
| Injection, solution, concentrate | Intravenous |
1000 mg/40mL
|
| Solution | Intravenous |
25 mg / mL
|
| Solution, concentrate | Intravenous |
1000 mg
|
| Solution, concentrate | Intravenous |
100000000 mg
|
| Injection, solution, concentrate | Parenteral |
1000 mg
|
| Injection, solution | Intravenous |
|
| Solution | Intravenous |
1000 mg/40mL
|
| Injection, solution, concentrate | Intravenous |
1000 mg
|
| Injection, solution, concentrate | Intravenous; Parenteral |
1000 MG
|